DCF Advisers’s Esperion Therapeutics ESPR Stock Holding History

DCF Advisers’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-250	Closed	-$555	–	101
2024 Q2	$555	Sell	250 -3,250	-93%	-$7.64K	﹤0.01%	94
2024 Q1	$9.38K	Buy	+3,500	New	+$8.51K	﹤0.01%	83

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

DCF Advisers's ESPR Position: Q2 2021 in Review

DCF Advisers sold out of Esperion Therapeutics (ESPR) in Q2 2021, closing a stake of 17,286 shares — an estimated $485K sold.

DCF Advisers first reported a position in ESPR in Q4 2019 and held it in 6 quarters. The position peaked at $2.49M in Q2 2020. 142 funds tracked by Wall St. Rank hold ESPR as of Q2 2021.

DCF Advisers reported no remaining Esperion Therapeutics position as of Q2 2021 after selling out during the quarter.
DCF Advisers sold 17,286 Esperion Therapeutics shares in Q2 2021, an estimated $485K.
DCF Advisers first reported a position in Esperion Therapeutics in Q4 2019 and held it in 6 quarters.
DCF Advisers's Esperion Therapeutics position peaked at $2.49M in Q2 2020.
142 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2021.

Based on DCF Advisers's 13F filing for Q2 2021, filed 13 Aug 2021.